Concerns about incretin mimetics 'inconsistent' with data

FDA and EMA said concerns about a causal association between glucagon-like peptide-1 (GLP-1) receptor agonists -- known as incretin mimetics -- and pancreatitis or pancreatic cancer are "inconsistent ...